Details:
NativusWell® contains a novel, non-hormonal bioactive ingredient DOI, having anti-ageing and antioxidant effect is designed to support the overall health of women undergoing perimenopause, menopause and postmenopause.
Lead Product(s): NativusWell
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: NativusWell
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2023
Details:
The combination will create one of the largest and fastest growing UK pharma companies and accelerated growth in current and future product portfolio, especially in healthcare (leading asset Akizza having gestodene/ethinylestradiol combination) in the UK and internationally.
Lead Product(s): Gestodene,Ethinyl Estradiol
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Akizza
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Aspire Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 03, 2022
Details:
NativusWell (dioscorea polystachya) contains a novel, non-hormonal bioactive ingredient DOI, designed to support health of women undergoing perimenopause, menopause and postmenopause.
Lead Product(s): Dioscorea Polystachya
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: NativusWell
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2022
Details:
Femarelle® is a non-hormonal food supplement developed to help women manage symptoms in perimenopause, products cover all menopause stages to improve symptoms and women's bone health and will be available in different countries.
Lead Product(s): Tofu Extract,Flaxeed
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Femarelle
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2022
Details:
Intrarosa is now available in this market as the first and only locally acting DHEA (dehydroepiandrosterone) treatment indicated for postmenopausal women experiencing moderate to severe symptoms associated with vulvovaginal atrophy (VVA).
Lead Product(s): Prasterone
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Intrarosa
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Endoceutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 14, 2022
Details:
The real world PRO-E2 safety study confirmed that the risk of venous thromboembolism is at least as low with Zoely (NOMAC-E2) as with levonorgestrel-containing combined oral contraceptives. NOMAC-E2 is only monophasic contraceptive pill using body-identical 17B-estradiol.
Lead Product(s): Nomegestrol Acetate,Estradiol
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Zoely
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2021
Details:
Estradiol Valerate Injection USP is indicated (i) in the treatment of vasomotor symptoms associated with menopause (ii) in the management of hormonal imbalances due to castration or primary ovarian failure (iii) in the treatment of androgen-dependent carcinoma of the prostate.
Lead Product(s): Estradiol Valerate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2021